 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...6162636465666768697071...858859» |
- | Prolia (denosumab) / Amgen
Retrospective data, Journal: The Effectiveness of Denosumab in Middle Eastern Patients With Giant Cell Tumor of the Bone: A Single-Center, Retrospective Study. (Pubmed Central) - May 16, 2024
Denosumab does not seem to provide superior long-term outcomes compared to surgery alone. Although our findings are generally consistent with other studies in the literature, larger long-term studies are needed to confirm our findings.
- | miransertib (MK-7075) / Merck (MSD), Ibrance (palbociclib) / Pfizer, Nerlynx (neratinib) / Puma
Journal, Combination therapy: Synergistic Effects of Neratinib in Combination With Palbociclib or Miransertib in Brain Cancer Cells. (Pubmed Central) - May 16, 2024
Notably, we found that treatment with neratinib in combination with palbociclib (CDK4/6 inhibitor), or miransertib (AKT1/2/3 inhibitor) resulted in synergistic growth inhibition of all HBCCLs. Our results support that repurposing drugs like neratinib in combination with the palbociclib or miransertib may be of therapeutic potential in brain cancer and warrants further investigations.
- | Ibrance (palbociclib) / Pfizer, Epidaza (chidamide) / Chipscreen, Verzenio (abemaciclib) / Eli Lilly
Journal, Metastases: Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2- metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China. (Pubmed Central) - May 16, 2024
Our results support that repurposing drugs like neratinib in combination with the palbociclib or miransertib may be of therapeutic potential in brain cancer and warrants further investigations. No abstract available
- | Ibrance (palbociclib) / Pfizer, Epidaza (chidamide) / Chipscreen, Verzenio (abemaciclib) / Eli Lilly
Journal, Metastases: Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2- metastatic breast cancer. (Pubmed Central) - May 16, 2024
Common non-hematological toxicity occurred in abemaciclib group was diarrhea (27.4%), and were increased aspartate aminotransferase (AST) (26.3%), nausea (25.0%), vomiting (11.8%) and hypokalemia (13.2%) in tucidinostat group. Our study suggests superiority of abemaciclib-based therapy over tucidinostat-based therapy in patients progressed on palbociclib, which merits further assessment in larger and prospective trials.
- | Ibrance (palbociclib) / Pfizer, Epidaza (chidamide) / Chipscreen, Verzenio (abemaciclib) / Eli Lilly
Journal, Metastases: Navigating next-generation HR+/HER2- metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression. (Pubmed Central) - May 16, 2024
Our study suggests superiority of abemaciclib-based therapy over tucidinostat-based therapy in patients progressed on palbociclib, which merits further assessment in larger and prospective trials. No abstract available
- ||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion date, Trial primary completion date: Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta (clinicaltrials.gov) - May 16, 2024
P3, N=106, Recruiting, Sponsor: Amgen
No abstract available Trial completion date: Sep 2027 --> May 2027 | Trial primary completion date: Jun 2027 --> Feb 2027
- | Enbrel (etanercept) / Pfizer, Amgen
Journal: Loeffler's Endocarditis- A cause of endomyocardial fibrosis in a patient of juvenile idiopathic arthritis: A Case Report. (Pubmed Central) - May 16, 2024
Her initial echocardiogram showed suspicion of Loeffler's Endocarditis, which is attributed to be an adverse effect of etanercept- a tumour necrosis factor (TNF) inhibitor, which she had been prescribed for her arthritis. The patient is currently being managed with high doses of steroids, therapeutic anticoagulation with rivaroxaban, carvedilol for tachycardia and mycophenolate mofetil as an immunosuppressant.
- | Krazati (adagrasib) / BMS
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) (clinicaltrials.gov) - May 16, 2024
P1, N=11, Active, not recruiting, Sponsor: Mirati Therapeutics Inc.
The patient is currently being managed with high doses of steroids, therapeutic anticoagulation with rivaroxaban, carvedilol for tachycardia and mycophenolate mofetil as an immunosuppressant. Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2023
- ||| tagtociclib (PF-07104091) / Pfizer
Enrollment closed, Enrollment change, Trial completion date, Combination therapy: PF-07104091 as a Single Agent and in Combination Therapy (clinicaltrials.gov) - May 16, 2024
P1/2, N=154, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2023 Recruiting --> Active, not recruiting | N=320 --> 154 | Trial completion date: Jan 2026 --> Mar 2025
- || fipaxalparant (AMG 670) / Amgen
Trial primary completion date: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) - May 16, 2024
P2, N=300, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=320 --> 154 | Trial completion date: Jan 2026 --> Mar 2025 Trial primary completion date: Jul 2025 --> Aug 2024
- | Ibrance (palbociclib) / Pfizer, Zynyz (retifanlimab-dlwr) / Incyte
Enrollment closed, Metastases: Palbociclib and INCMGA00012 in People With Advanced Liposarcoma (clinicaltrials.gov) - May 16, 2024
P2, N=42, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jul 2025 --> Aug 2024 Recruiting --> Active, not recruiting
- | Journal: Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (Pubmed Central) - May 15, 2024
Recruiting --> Active, not recruiting The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA.
- | Journal, Metastases: Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. (Pubmed Central) - May 15, 2024
A cautious approach to systemic therapy is recommended for patients with Child-Pugh class B advanced HCC. Further guidance on choosing between options is included within the guideline.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
- | Journal: Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation. (Pubmed Central) - May 15, 2024
Further guidance on choosing between options is included within the guideline.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines. Interruption of antipsoriatic oral and biologic therapies is generally not necessary for
- | solitomab (AMG 110) / Amgen
Journal: Genome-wide association study and genomic selection of spike-related traits in bread wheat. (Pubmed Central) - May 15, 2024
Additionally, the eight stable and major MTAs, including MTA259, MTA64, MTA66, MTA94, MTA110, MTA165, MTA180, and MTA164, were converted into cost-effective and efficient detection markers. This study provided valuable genetic resources and reliable molecular markers for wheat breeding programs.
- | Lumakras (sotorasib) / Amgen
Journal, Real-world evidence, Real-world effectiveness, Real-world: Brief Report: Real-World Efficacy and Safety of (Pubmed Central) - May 15, 2024
Toxicities leading to sotorasib interruption, dose reduction, or discontinuation were common. Sotorasib dose reduction was associated with improved survival, suggesting that sotorasib dose reduction may not compromise efficacy.
- | Prolia (denosumab) / Amgen
Journal: Osteoporosis management in Australian aged care facilities: a mixed method study. (Pubmed Central) - May 15, 2024
A need to raise awareness of aged care-specific consensus recommendations concerning vitamin D and calcium is evident. Facility protocols and procedures must be developed and implemented to ensure safe and effective use of denosumab.
- | triciribine phosphate (PTX-200) / VioQuest, Prescient Therap
Journal: Identification of triciribine as a novel myeloid cell differentiation inducer. (Pubmed Central) - May 15, 2024
Real-time PCR analysis demonstrated that components of these pathways including IL1?, CD3D, IL5RA, ITGA6, CD44, ITGA2B, CD37, CD9, CSF2RA, and IL3RA, were upregulated by TCN-induced differentiation. Collectively, we identified TCN as a novel myeloid cell differentiation inducer, and trials of TCN for APL and non-APL leukemia are worthy of exploration in the future.
- || Neulasta (pegfilgrastim) / Roche
Clinical, Journal: Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors-a questionnaire study. (Pubmed Central) - May 15, 2024
In addition, physicians seem more inclined to prescribe G-CSF to adjuvant/neoadjuvant patients rather than metastatic patients. Finally, the type of chemotherapy tends to be a more significant determining factor than the patient's background.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Reduction of plasma CGRP levels in migraine patients treated with erenumab or galcanezumab. (Pubmed Central) - May 15, 2024
Finally, the type of chemotherapy tends to be a more significant determining factor than the patient's background. No abstract available
- camsirubicin (MNPR-201) / Monopar Therap
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: Camsirubicin + Pegfilgrastim to Determine MTD in ASTS (clinicaltrials.gov) - May 15, 2024
P1, N=14, Terminated, Sponsor: Monopar Therapeutics
No abstract available N=21 --> 14 | Trial completion date: Jun 2025 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Oct 2023; lack of timely enrollment
- |||| Imlygic (talimogene laherparepvec) / Amgen
Trial completion date, Trial primary completion date: Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC (clinicaltrials.gov) - May 15, 2024
P=N/A, N=300, Recruiting, Sponsor: Amgen
N=21 --> 14 | Trial completion date: Jun 2025 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Oct 2023; lack of timely enrollment Trial completion date: Aug 2037 --> Aug 2038 | Trial primary completion date: Aug 2037 --> Aug 2038
- Venclexta (venetoclax) / Roche, AbbVie, tapotoclax (AMG 176) / Amgen
TARGETING MCL1-DRIVEN ANTI-APOPTOTIC PATHWAYS OVERCOMES BLAST PROGRESSION AFTER HYPOMETHYLATING AGENT RESISTANCE IN CHRONIC MYELOMONOCYTIC LEUKEMIA (Hall N104) - May 15, 2024 - Abstract #EHA2024EHA_4253;
Trial completion date: Aug 2037 --> Aug 2038 | Trial primary completion date: Aug 2037 --> Aug 2038 NF-kB
- briquilimab (JSP191) / Jasper Therap
BRIQUILIMAB POTENTLY INHIBITS SCF/C-KIT SIGNALING, WHICH DOES NOT INDUCE HEALTHY HUMAN HEMATOPOIETIC STEM CELL (HSC) APOPTOSIS, BUT SKEWS HSC DIFFERENTIATION POTENTIAL. (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3962;
Briquilimab potently blocks SCF/c-Kit signaling by inhibiting SCF binding to c-Kit. Blocking of SCF/c-Kitsignaling by briquilimab does not cause increased HSC apoptosis but skews HSC towards a distinct alternativeHSC differentiation pathway in ex vivo culture.
- renizgamglogene autogedtemcel (EDIT-301) / Editas Medicine
RENI-CEL, THE FIRST ASCAS12A GENE-EDITED CELL THERAPY, SHOWS PROMISING PRELIMINARY RESULTS IN KEY CLINICAL OUTCOMES IN TRANSFUSION-DEPENDENT BETA-THALASSEMIA PATIENTS TREATED IN THE EDITHAL TRIAL (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3933;
P1/2
Autologous CD34+hematopoietic stem and progenitor cells are collected by apheresis after plerixafor + filgrastim mobilizationand edited at the HBG1/2 promoters with the highly efficient and specific, proprietary gene editing nuclease,AsCas12a. After myeloablative conditioning with busulfan, patients received a single infusion of reni-cel (aminimum of 3
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis
THE CLINICAL EFFICACY OF TPO RECEPTOR AGONISTS IN PROMOTING PLATELET RECOVERY AFTER INTENSIVE IMMUNOSUPPRESSION COMBINED WITH UMBILICAL CORD BLOOD TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA. () - May 15, 2024 - Abstract #EHA2024EHA_3771;
The results showed that in the TPO-RA cohort, 13 patients achieved platelet recovery after treatment, with 8achieving complete remission and 5 achieving partial remission. The time to reach certain platelet counts wasalso recorded, such as a median time of 30 days (range: 6-69 days) for platelet counts to exceed 20
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Roche
RESPONSE AND OUTCOME OF PATIENTS WITH APLASTIC ANEMIA ARISING FROM ACQUIRED AMEGAKARYOCYTIC THROMBOCYTOPENIA () - May 15, 2024 - Abstract #EHA2024EHA_3740;
In conclusion, our data, limited by the small patient number, suggest that AA patients arising from AAT showpoor response to standard AA treatment. Further data are needed to better understand the pathophysiology ofATR and the progression to AA.
- Nplate (romiplostim) / Amgen, Kyowa Kirin
PREDICTIVE FACTORS FOR THE RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IST-REFRACTORY APLASTIC ANEMIA: DATA FROM TWO CLINICAL TRIALS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3724;
P2, P2/3
Further data are needed to better understand the pathophysiology ofATR and the progression to AA. Background: Romiplostim, a thrombopoietin receptor agonist, has been reported to be effective and safe for treatingimmune suppressive therapy (IST)- or eltrombopag-refractory aplastic anemia (AA) and for IST-na
- Nplate (romiplostim) / Amgen, Kyowa Kirin
EFFICACY OF ROMIPLOSTIM IN NEWLY DIAGNOSED APLASTIC ANAEMIA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3705;
The adverse events were grade 1 CTCAE and manageable. Romiplostim appears to offer a compelling alternative option to Eltrombopag, and these findings need tobe ratified by studies on larger cohorts.
- Epysqli (eculizumab biosimilar) / AffaMed Therap, Samsung, Soliris (eculizumab) / AstraZeneca, Bkemv (eculizumab-aeeb) / Amgen
EVALUATION OF HEREDITARY FRUCTOSE TOLERANCE IN PREVALENT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, HEMOLYTIC UREMIC SYNDROME, OR MYASTHENIA GRAVIS (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3639;
By analyzing decades of patient medical records and claims data from the US, Germany and the UK, thelikelihood for a patient of having both HFI and eculizumab indicated conditions is very low. If HFI is suspected,a detailed symptom history should be collected prior to initiating treatment with biosimilar ABP 959.
- Blincyto (blinatumomab) / Astellas, Amgen
BLINATUMOMAB ADDED TO PREPHASE AND CONSOLIDATION THERAPY IN ADULT B-ALL: A COMPARISON OF THE CONSECUTIVE HOVON-100 AND H-146 STUDIES (Hall N104) - May 15, 2024 - Abstract #EHA2024EHA_3595;
P2
More side effects were encountered in patients >60y of age. Toxicities necessitatedchemotherapy dose adaptations, after which no further significant safety concerns were noted.
- Blincyto (blinatumomab) / Astellas, Amgen
BLINATUMOMAB AS CONSOLIDATION IN A PAEDIATRIC PROTOCOL LEADS TO HIGH RATES OF END-CONSOLIDATION MRD NEGATIVITY AND EXCELLENT OUTCOMES IN AYA ALL (Hall N104) - May 15, 2024 - Abstract #EHA2024EHA_3594;
We plan to take this platform forward in a larger study while introducing novel therapies in HR blocksto improve MRDneg rates in those already exposed to blinatumomab prior to SCT. Fig 1.
- Blincyto (blinatumomab) / Astellas, Amgen
BLINATUMOMAB FOR FIRST LINE TREATMENT IN INTERMEDIATE AND HIGH RISK DOWN SYNDROME B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA: INITIAL FINDINGS FROM THE ALLTOGETHER1 DS TRIAL (Hall N104) - May 15, 2024 - Abstract #EHA2024EHA_3593;
Although there wasan improved overall toxicity profile compared to UKALL 2011 consolidation, the increased rate of seizures inpatients >10 yrs, means we are now trialling earlier and increased doses of levetiracetam. Thus far, we have noTRM from the commencement of blinatumomab, nor any relapse events.
- Blincyto (blinatumomab) / Astellas, Amgen
SINGLE-CELL RNA-SEQUENCING REVEALS THE ACTION MECHANISM OF BLINATUMOMAB IN PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3436;
It induces theeffector CD8+ T cells especially of several certain types to confront tumor cells, then some of the cells wereconverted to exhaustive T-cells (Figure 1C). Also, myeloid cells in the immune microenvironment contribute tothe tumor conquer may through phagocytosis.
- Blincyto (blinatumomab) / Astellas, Amgen
GENOMIC CHARACTERIZATION OF PH- B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS ENROLLED IN THE GIMEMA LAL2317 TRIAL (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3422;
Clinical correlate analysis confirms the negative impact of the Ph-likesignature, and, with the caveat of the small patient size, also of MEF2D rearrangements and TP53 mutation. 1.
- Epogen (epoetin alfa) / Amgen, Monofer (iron isomaltoside 1000) / Pharmacosmos
THE INFLUENCE OF INFLAMMATORY CYTOKINES AND HEPSIDIN ON THE DEVELOPMENT OF ANEMIA AND THE EFFECTIVENESS OF ANEMIA CORRECTION WITHOUT RED BLOOD TRANSFUSIONS IN GASTRIC CANCER AFTER NEOADJUVANT THERAPY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3344;
Anemia in gastric cancer patients who received neoadjuvant therapy is not due to hepcidin hyperproduction,but to the negative effect of chemotherapy on erythropoiesis and iron deficiency, which made it possible toachieve a positive effect of erythropoietin and intravenous iron therapy in 91. 3% of patients.
- Neulasta (pegfilgrastim) / Roche
A PROSPECTIVE, MULTICENTER STUDY ON STEM CELL MOBILIZATION WITH ETOPOSIDE + CYTARABINE PLUS PEGFILGRASTIM AS THE FIRST-LINE MOBILIZATION IN PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMA () - May 15, 2024 - Abstract #EHA2024EHA_3174;
P=N/A
- plerixafor / Generic mfg.
A PREEMPTIVE FIXED DOSE OF 12 MG OF PLERIXAFOR PLUS HIGH-VOLUME APHERESIS IS AN EFFICIENT AND COST-EFFECTIVE ALTERNATIVE TO RESCUE POOR MOBILIZER PATIENTS WITH MYELOMA OR LYMPHOMA () - May 15, 2024 - Abstract #EHA2024EHA_3173;
9%) and safe inrescuing poor mobilizer patients. Considering the stability of the product, nearly 84 days (2), it is possible touse just one vial for two doses or two patients.
- Blincyto (blinatumomab) / Astellas, Amgen
CURATIVE EFFICACY ANALYSIS OF ALLO-HSCT USING SHORT-TERM BLINATUMOMAB COMBINED WITH TRADITIONAL CONDITIONING REGIMEN FOR B CELL ACUTE LYMPHOBLASTIC LEUKEMIA () - May 15, 2024 - Abstract #EHA2024EHA_3166;
Considering the stability of the product, nearly 84 days (2), it is possible touse just one vial for two doses or two patients. Short-term blinatumomab-enhanced conditioning regimens are well-tolerated and can improve the prognosisfor patients with MRD-positive B-ALL before allo-HSCT.
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION RESULTS IN SIGNIFICANT ECONOMIC BURDEN. () - May 15, 2024 - Abstract #EHA2024EHA_3136;
Patients with PGF have significantly higher costs of care and length of stay. This is consistent with the highdegree of medical management compared to GGF.
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
PERIPHERAL BLOOD STEM CELL COLLECTION IN ALLOGENEIC DONORS: HOW TO PREDICT CD34+ COUNT IN PRODUCT. (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3080;
The higher results of CD34(+) per kg of donor bw are seen in males, however they are more diversifiedby total weight. In females the results are more comparable regardless of total body weight.
- pomalidomide / Generic mfg.
THE CLINICAL OUTCOME ON THE PREVENTION OF RELAPSE OF ACUTE B-LYMPHOCYTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POMALIDOMIDE (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3071;
Pomalidomide can effectively prevent relapse of B-ALL patients after allo-HSCT, and its safety is controllable. Inthe future, the effectiveness and safety of Pomalidomide will be verified by a multicenter, prospectiverandomized controlled studies.
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Rituxan (rituximab) / Roche
REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA IN PREGNANCY: DISTRICT GENERAL HOSPITAL EXPERIENCE IN MANAGING CLINICAL AND BIO-PSYCHO-SOCIAL COMPLEXITIES RELATED TO THROMBOPOIETIN RECEPTOR AGONISTS () - May 15, 2024 - Abstract #EHA2024EHA_3000;
Furtherresearch is needed to clarify the safety and efficacy of therapies such as TPO-RAs in refractory ITP associatedwith pregnancy. This case highlights the importance of multidisciplinary collaboration, showing that these complex patients canbe managed safely in their local DGH, providing that the experts are part of the decision-making process.
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Rituxan (rituximab) / Roche
CYCLIC THROMBOCYTOPENIA: A CASE SERIES FROM MAYO CLINIC () - May 15, 2024 - Abstract #EHA2024EHA_2991;
In our experience, it is a chronic disease, and we did not observe spontaneous remissions. None of the ITPtreatments were effective.
- OUTCOMES OF COMBINATION THERAPY FOR PATIENTS WITH CHRONIC REFRACTORY ITP: INSIGHTS FROM A SINGLE-CENTRE EXPERIENCE () - May 15, 2024 - Abstract #EHA2024EHA_2989;
There is a paucity of real-world outcomes of Fostamatinib and Sirolimus based combination regimesfor refractory ITP. Although the patient cohorts are small, the outcomes are reassuring.
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis
THERAPY OF IMMUNE THROMBOCYTOPENIA WITH THROMBOPOIETIN RECEPTOR AGONISTS IN THE SECOND AND SUBSEQUENT LINES. () - May 15, 2024 - Abstract #EHA2024EHA_2988;
Romiplostim wasadministered to 339 patients, and eltrombopag to 117 patients. The study confirmed the effectiveness of the use of TPO-RAs in the second andsubsequent lines of ITP therapy, as well as showed the posibility of achieving complete platelet response whenswitching from one TPO-RA to an alternative.
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
IMPACT OF THROMBOPOIETIN RECEPTOR AGONISTS AND ADHERENCE TO INSTRUCTIONS FOR TREATMENT OF PRIMARY CHRONIC IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF A REAL-WORLD CROSS-SECTIONAL INTERNATIONAL SURVEY () - May 15, 2024 - Abstract #EHA2024EHA_2982;
The study confirmed the effectiveness of the use of TPO-RAs in the second andsubsequent lines of ITP therapy, as well as showed the posibility of achieving complete platelet response whenswitching from one TPO-RA to an alternative. Background: Thrombopoietin receptor agonists (TPO-RAs)
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
EFFICACY OF HETROMBOPAG IN TREATMENT OF CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA IN ACUTE MYELOID LEUKEMIA PATIENTS () - May 15, 2024 - Abstract #EHA2024EHA_2978;
The treatment of hetrombopag for chemotherapy-induced thrombocytopenia in patients with acute myeloidleukemia has a certain effect, it can rapidly increase platelet count, reduce platelet transfusion dependence. Further validation with large sample size and prospective clinical studies are needed.
- Doptelet (avatrombopag) / SOBI
AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIA (ITP): A REAL LIFE SINGLE CENTRE EXPERIENCE IN 20 CONSECUTIVE PATIENTS () - May 15, 2024 - Abstract #EHA2024EHA_2976;
In addition, patients have better adherence totreatment due to low adverse effects and good tolerability. Table 1.
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis
TREATMENT OUTCOMES OF TPO-RECEPTOR AGONISTS IN PATIENTS WITH STEROID-REFRACTORY IMMUNE THROMBOCYTOPENIA; CONDITIONS FOR DISCONTINUATION WITH SUSTAINED PLATELET RESPONSE () - May 15, 2024 - Abstract #EHA2024EHA_2969;
Our real-world data confirmed the efficacy of TPO-RA in steroid-refractory ITP and suggested possibility ofdiscontinuation in good responders with early TPO-RA treatment and low autoimmune disease burden. Thisemphasizes the potential for personalized treatment strategies in managing ITP.